Pith. sign in

REVIEW 2 cited by

Latent Molecular Optimization for Targeted Therapeutic Design

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 1809.02032 v1 pith:7BPKVQYO submitted 2018-09-05 cs.AI cs.LGcs.NEq-bio.BM

classification cs.AIcs.LGcs.NEq-bio.BM
keywords bindingmolecularpropertiesspacetargetaffinityapproachchemical
verification ladder T0 review T1 audit T2 compute T3 formal

Signed reviews

No signed human review yet.

0 comments
read the original abstract

We devise an approach for targeted molecular design, a problem of interest in computational drug discovery: given a target protein site, we wish to generate a chemical with both high binding affinity to the target and satisfactory pharmacological properties. This problem is made difficult by the enormity and discreteness of the space of potential therapeutics, as well as the graph-structured nature of biomolecular surface sites. Using a dataset of protein-ligand complexes, we surmount these issues by extracting a signature of the target site with a graph convolutional network and by encoding the discrete chemical into a continuous latent vector space. The latter embedding permits gradient-based optimization in molecular space, which we perform using learned differentiable models of binding affinity and other pharmacological properties. We show that our approach is able to efficiently optimize these multiple objectives and discover new molecules with potentially useful binding properties, validated via docking methods.

Discussion (0). Continue with ORCID to comment.

Forward citations

Cited by 2 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. PaccMann$^{RL}$: Designing anticancer drugs from transcriptomic data via reinforcement learning

    q-bio.BM 2019-08 conditional novelty 6.0 of 10

    A two-VAE generative model, fine-tuned with reinforcement learning and a drug-sensitivity critic, produces molecules with high predicted efficacy against specific cancer transcriptomic profiles, but only in silico.

  2. DeepScaffold: a comprehensive tool for scaffold-based de novo drug discovery using deep learning

    q-bio.QM 2019-08 conditional novelty 4.0 of 10

    DeepScaffold generates valid, drug-like molecules that retain a given scaffold, and it extends scaffold-based generation to cyclic skeletons and side-chain property queries.

Pith tools